DiscoverThe Lancet HIV
The Lancet HIV
Claim Ownership

The Lancet HIV

Author: The Lancet HIV

Subscribed: 19Played: 77


Peter Hayward, Editor-in-Chief of The Lancet HIV, and Philippa Harris, Deputy Editor, speak to the journal’s authors to explore their research and its impact on people’s health, health care, and health policy in this regular podcast.
37 Episodes
Dr Jessica Castilho (Vanderbilt University Medical Centre) and Dr Claudia Cortes (University of Chile School of Medicine) join Peter Hayward to discuss their research on life expectancy for people living with HIV in Latin America and the Caribbean. 
Professor Chloe Orkin (Queen Mary University London, UK) joins Peter Hayward to talk about long-acting cabotegravir for HIV treatment and the 96 weeks of the FLAIR study.
Sarah Calabrese (George Washington University, USA) talks to Deputy Editor Philippa Harris about prioritising sexual pleasure and correcting misinformation in the era of U=U.
Le Minh Giang (Hanoi Medical University, Vietnam) and Todd Korthuis (Oregon Health and Science University, USA) discuss their work in Vietnam on treating opioid use disorder in people with HIV with Deputy Editor Philippa Harris.
In a bumper edition, we talk to contributors to several papers in the December issue on diverse topics that include test-and-treat in correctional facilities, PrEP engagement in transgender women, the burden of living with HIV in MSM, and gentrification in San Francisco. 
Deputy Editor Philippa Harris discusses HIV testing and the HOSENG trial with researchers Mathebe Kopo (SolidarMed, Lesotho) and Alain Amstutz (Swiss Tropical and Public Health Institute, Basel, Switzerland).
Susannah Mayhew (London School of Hygiene and Tropical Medicine) joins Deputy Editor Philippa Harris to discuss integration of sexual and reproductive health and HIV services. 
Editor-in-Chief, Peter Hayward, talks to researchers from London School of Hygiene and Tropical Medicine and Melanie Alufandika-Moyo Malawi-Liverpool Wellcome Trust about their research on virological failure and HIV drug resistance in patients with HIV in hospital in Malawi.
Researchers from the Medical Research Council Clinical Trials Unit at University College London join Editor-in-Chief Peter Hayward to discuss paediatric HIV treatment and the pharmacokinetic substudy of the ODYSSEY trial of dolutegravir for children with HIV.
Deputy Editor Philippa Harris talks to Chi-Chi Udeagu (New York City Department of Health and Mental Hygiene, USA) about HIV partner services in New York City and the impact of COVID-19. 
Kelly Dooley (Johns Hopkins University, USA) and Gavin Churchyard (Aurum Institute, South Africa) discuss their trial on tuberculosis prevention in people with HIV taking dolutegravir-based antiretroviral therapy with Deputy Editor Philippa Harris. 
Adam Castillejo joins The Lancet HIV’s Editor, Peter Hayward, to talk about his experience of HIV, cancer, and becoming the second person to be cured of HIV.
Deputy Editor Philippa Harris discusses viral load testing with Paul Drain (University of Washington, USA) and a trial of point-of-care testing with task shifting to improve treatment outcomes.
Joseph Kagaayi (Rakai Health Sciences Program, Uganda) and Oliver Ratman (Imperial College London, UK) talk to Editor-in-Chief Peter Hayward about the world famous research site and the insights that deep sequencing has provided into the flow of HIV in their latest research.
Marta Nunes (University of the Witwatersrand, Johannesburg, South Africa) talks to Philippa Harris about vaccination response in people living with HIV and a trial of influenza vaccine dosing in pregnant women with HIV in South Africa.
Living well with HIV

Living well with HIV


For World AIDS day, The Lancet HIV Deputy Editor Philippa Harris talks to Jeff Lazarus and Nikos Dedes about the importance of good health-related quality of life and the barriers people living with HIV face in achieving this.
HIV vaccines

HIV vaccines


Giuseppe Pantaleo (Service of Immunology and Allergy, Department of Medicine, Lausanne University Hospital, Switzerland) tells Peter Hayward about a phase 1 vaccine study published in the November issue of The Lancet HIV, and gives an overview of the HIV vaccine field.
Julia Marcus and Douglas Krakower talk to Peter Hayward about the use of electronic health record data to predict HIV risk and identify PrEP candidates.
Third-line therapy

Third-line therapy


The Lancet HIV Editor Peter Hayward talks to Beatriz Grinsztejn (Evandro Chagas National Institute of Infectious Diseases, Fiocruz, Rio de Janeiro, Brazil) about ACTG A5288, an international, multiarm trial investigating management of second-line treatment failure
The Lancet HIV Deputy Editor Philippa Harris talks to Betsy Herold (Albert Einstein College of Medicine, USA) about her trial investigating a tenofovir disoproxil fumarate intravaginal ring for pre-exposure prophylaxis in sexually active women.
Download from Google Play
Download from App Store